Report of transactions with shares and related securities of NeuroSearch by
persons discharging managerial responsibilities and person/companies closely
associated with these

Pursuant to section 28a of the Danish Act on Securities Trading, NeuroSearch
A/S (NEUR.CO) shall make public transactions with shares and related securities
of NeuroSearch A/S by persons discharging managerial responsibilities and
persons/companies closely associated with these.

Name: Dan Peters
Reason: Vice President, Director of Medicinal Chemistry
Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666
Transaction: Purchase of shares
Trading date: 4 March 2009
Market: The Nasdaq OMX Copenhagen A/S
Number (pcs): 1,200
Market value (DKK):96,000

Contact person:
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate
Communications, telephone: +45 4017 5103



NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq
OMX Copenhagen. The company's core business covers the development of novel
drugs, based on a broad and well-established drug discovery platform focusing
on ion channels and CNS disorders. A substantial share of NeuroSearch's
activities is partner financed through an alliance with Eli Lilly and Company
and collaborations with GlaxoSmithKline (GSK) and Abbott. The drug pipeline
comprises 8 clinical (Phase I-III) development programmes: ACR16 for
Huntington's disease (Phase III), tesofensine for obesity (Phase III ready),
ABT-894 for ADHD (Phase II) in partnership with Abbott, ACR325 for Parkinson's
disease (Phase II ready), ABT-107 and ABT-560 for the treatment of various CNS
disorders - both (Phase I) in collaboration with Abbott, ACR343 for
schizophrenia (Phase II ready) and NSD-788 for anxiety/depression (Phase I). In
addition, NeuroSearch has a broad portfolio of preclinical drug candidates and
holds equity interests in several biotech companies.